RT Journal Article
SR Electronic
T1 The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256520
DO 10.1101/2021.05.03.21256520
A1 Föhse, F. Konstantin
A1 Geckin, Büsranur
A1 Overheul, Gijs J.
A1 van de Maat, Josephine
A1 Kilic, Gizem
A1 Bulut, Ozlem
A1 Dijkstra, Helga
A1 Lemmers, Heidi
A1 Sarlea, S. Andrei
A1 Reijnders, Maartje
A1 Hoogerwerf, Jacobien
A1 Oever, Jaap ten
A1 Simonetti, Elles
A1 van de Veerdonk, Frank L.
A1 Joosten, Leo A.B.
A1 Haagmans, Bart L.
A1 van Crevel, Reinout
A1 Li, Yang
A1 van Rij, Ronald P.
A1 GeurtsvanKessel, Corine
A1 de Jonge, Marien I.
A1 Domínguez-Andrés, Jorge
A1 Netea, Mihai G.
YR 2021
UL http://medrxiv.org/content/early/2021/05/06/2021.05.03.21256520.abstract
AB The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.Competing Interest StatementM.G.N and L.A.B.J are scientific founders of Trained Therapeutix and Discovery.Clinical TrialEudraCT 2021-000182-33Funding StatementY.L. was supported by an ERC Starting Grant (#948207) and the Radboud University Medical Centre Hypatia Grant (2018) for Scientific Research. J.D-A. is supported by The Netherlands Organization for Scientific Research (VENI grant 09150161910024). M.G.N. was supported by an ERC Advanced Grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Arnhem-Nijmegen Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study are available upon request.